Cart
sales@molnova.com
TAS6417
CAS No. 1661854-97-2
TAS6417( —— )
Catalog No. M23746 CAS No. 1661854-97-2
TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 215 | In Stock |
|
| 2MG | 120 | In Stock |
|
| 5MG | 188 | In Stock |
|
| 10MG | 312 | In Stock |
|
| 25MG | 629 | In Stock |
|
| 50MG | 821 | In Stock |
|
| 100MG | 1107 | In Stock |
|
| 200MG | 1516 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTAS6417
-
NoteResearch use only, not for human use.
-
Brief DescriptionTAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC.
-
DescriptionTAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC (IC50: ranging from 1.1-8.0 nM).
-
In VitroApoptosis Analysis Cell Line:PC-9, H1975, BID007, BID019, BEAS-2B cells.Concentration:0-10 μM.Incubation Time:24-48 h.Result:Led to apoptosis via inhibition of mutant EGFR.
-
In VivoAnimal Model:Mice implanted with NCI-H1975 EGFR D770_N771insSVD xenografts.Dosage:50 and 100 mg/kg.Administration:Orally once daily for 14 days.Result:Showed marked tumor growth inhibition with treatment/control (T/C) ratios of 51% and 19%, respectively.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis|EGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1661854-97-2
-
Formula Weight396.44
-
Molecular FormulaC23H20N6O
-
Purity>98% (HPLC)
-
SolubilityDMSO:125 mg/mL (315.31 mM)
-
SMILESCC1=C[C@@H](CN2C1=C(C3=C(N=CN=C32)N)C4=CC5=CC=CC=C5N=C4)NC(=O)C=C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hasako S, et al. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658.
molnova catalog
related products
-
ACBI1
ACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2 and SMARCA4, also degrades the polybromo-associated BAF (PBAF) complex member PBRM1, with DC50s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively.
-
SACLAC
SACLAC is a cysteine asparaginase activation inhibitor with antitumor activity that decreases AML cell viability, inhibits AML cell proliferation, increases AML cell death, and induces apoptosis of AML cells, and is used in the study of acute myeloid leukemia and cancer.
-
HBDDE
HBDDE is a selective model inhibitor of the isoenzymes PKCα and PKCγ with IC 50 s of 43 μM and 50 μM, respectively.HBDDE has a higher affinity for PKCα/PKCγ than the PKCδ, PKCβI, and PKCβII isoenzymes.
